A Phase 2a, Double-blind, Randomized, Placebo-controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Presbidrops (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Orasis Pharmaceuticals
- 31 Jul 2017 Status changed from recruiting to completed.
- 19 Mar 2017 Planned End Date changed from 1 Oct 2016 to 1 Jul 2017.
- 19 Mar 2017 Planned primary completion date changed from 1 Aug 2016 to 1 May 2017.